↓ Skip to main content

Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

Overview of attention for article published in Alzheimer's Research & Therapy, September 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
6 news outlets

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
16 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
Published in
Alzheimer's Research & Therapy, September 2018
DOI 10.1186/s13195-018-0409-4
Pubmed ID
Authors

Susanne Ostrowitzki, Robert A. Lasser, Ernest Dorflinger, Philip Scheltens, Frederik Barkhof, Tania Nikolcheva, Elizabeth Ashford, Sylvie Retout, Carsten Hofmann, Paul Delmar, Gregory Klein, Mirjana Andjelkovic, Bruno Dubois, Mercè Boada, Kaj Blennow, Luca Santarelli, Paulo Fontoura, for the SCarlet RoAD Investigators

Abstract

Following publication of the original article [1], the author reported errors in the formatting of the table. The details of the errors are as follows.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 16 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 6 38%
Student > Master 2 13%
Other 2 13%
Student > Ph. D. Student 1 6%
Student > Bachelor 1 6%
Other 1 6%
Unknown 3 19%
Readers by discipline Count As %
Unspecified 6 38%
Pharmacology, Toxicology and Pharmaceutical Science 2 13%
Chemistry 2 13%
Medicine and Dentistry 2 13%
Neuroscience 1 6%
Other 1 6%
Unknown 2 13%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 44. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 October 2018.
All research outputs
#807,188
of 23,105,443 outputs
Outputs from Alzheimer's Research & Therapy
#94
of 1,252 outputs
Outputs of similar age
#19,270
of 341,808 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#2
of 35 outputs
Altmetric has tracked 23,105,443 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,252 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.8. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,808 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.